Healthcare / Drug Manufacturers - Specialty & GenericKSE
$7260.00
-160.00 (-2.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-7.0B · quality 32.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$154.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-26.0%
↓Gross Margin
36.7%
↓Debt/Equity
1.23
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.4%
FCF CAGR
—
FCF margin
-3.3%
FCF / Net income
0.20x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $210.25B · net income $-34.66B · FCF $-6.95B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $210.25B | $210.25B | $219.70B | $196.35B | $179.68B |
| Net Income | $-34.66B | $-34.66B | $-5.63B | $1.66B | $-28.3M |
| EBITDA | $-19.14B | $-19.14B | $8.71B | $10.34B | $10.31B |
| EPS | -1633.00 | -1633.00 | -313.00 | 115.00 | -1.82 |
| Gross Margin | 36.7% | 36.7% | 36.8% | 37.7% | 37.6% |
| Operating Margin | -10.6% | -10.6% | 0.1% | 3.3% | 2.2% |
| Net Margin | -16.5% | -16.5% | -2.6% | 0.8% | -0.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.23 | 1.23 | 0.85 | 1.38 | 1.27 |
| Current Ratio | 0.46 | 0.46 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-6.95B | $-6.95B | $-3.02B | $-12.65B | $-44.50B |
| Returns | |||||
| ROE | -26.0% | -26.0% | -3.2% | 1.3% | -0.0% |
| Valuation | |||||
| P/E | — | — | — | 65.91 | — |
| EV/EBITDA | — | — | 45.31 | 27.50 | 27.28 |
| P/B | 1.16 | 1.16 | 1.42 | 0.86 | 0.98 |
| Growth & Yield | |||||
| Revenue Growth | -4.3% | -4.3% | 11.9% | 9.3% | — |
| EPS Growth | -421.7% | -421.7% | -372.2% | 6425.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-313.00 → -1633.00
Residual
-37.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.